Ganglioside treatment of vincristine-induced neuropathy. An electrophysiologic study
- PMID: 3376136
- DOI: 10.1016/0300-483x(88)90015-7
Ganglioside treatment of vincristine-induced neuropathy. An electrophysiologic study
Abstract
A 5-week treatment with vincristine (0.20 or 0.25 mg/kg, i.v., once/week) in the rabbit produced a peripheral neuropathy characterized by both morphologic and electrophysiologic alterations. In particular, electrophysiologic recordings demonstrated that the amplitude, area and conduction velocity of compound action potential (CAP) were consistently reduced in a dose-dependent manner. The simultaneous daily administration of 50 mg/kg ganglioside mixture counteracted significantly this functional impairment, area and amplitude of the monophasic CAP being maintained closer to control values. These results suggest that the loss of functional nerve fibers can be reduced, in vincristine-induced neuropathy, by ganglioside treatment.
Similar articles
-
Vincristine-induced neuropathy in rat: electrophysiological and histological study.Exp Brain Res. 2006 Aug;173(2):334-45. doi: 10.1007/s00221-006-0499-2. Epub 2006 May 31. Exp Brain Res. 2006. PMID: 16736180
-
Efficacy of ganglioside treatment in reducing functional alterations induced by vincristine in rabbit peripheral nerves.Cancer Chemother Pharmacol. 1990;26(1):31-6. doi: 10.1007/BF02940290. Cancer Chemother Pharmacol. 1990. PMID: 2322988
-
Effect of gangliosides on nerve conduction velocity during diabetic neuropathy in the rat.Arch Int Pharmacodyn Ther. 1987 Jun;287(2):211-23. Arch Int Pharmacodyn Ther. 1987. PMID: 3307667
-
Experimental electrophysiologic recordings. Interpretation of the compound action potential.Clin Plast Surg. 1984 Jan;11(1):39-45. Clin Plast Surg. 1984. PMID: 6368097 Review. No abstract available.
-
Clinical electrophysiologic peripheral nerve recordings.Clin Plast Surg. 1984 Jan;11(1):47-52. Clin Plast Surg. 1984. PMID: 6368098 Review. No abstract available.
Cited by
-
Lack of neuroprotection by an ACTH (4-9) analogue. A randomized trial in patients treated with vincristine for Hodgkin's or non-Hodgkin's lymphoma.J Cancer Res Clin Oncol. 2004 Mar;130(3):153-60. doi: 10.1007/s00432-003-0524-9. Epub 2004 Jan 16. J Cancer Res Clin Oncol. 2004. PMID: 14727106 Free PMC article. Clinical Trial.
-
Vincristine-induced neuropathy in rat: electrophysiological and histological study.Exp Brain Res. 2006 Aug;173(2):334-45. doi: 10.1007/s00221-006-0499-2. Epub 2006 May 31. Exp Brain Res. 2006. PMID: 16736180
-
Ganglioside-monosialic acid (GM1) for prevention of chemotherapy-induced peripheral neuropathy: a meta-analysis with trial sequential analysis.BMC Cancer. 2021 Nov 2;21(1):1173. doi: 10.1186/s12885-021-08884-4. BMC Cancer. 2021. PMID: 34727879 Free PMC article.
-
Efficacy of ganglioside treatment in reducing functional alterations induced by vincristine in rabbit peripheral nerves.Cancer Chemother Pharmacol. 1990;26(1):31-6. doi: 10.1007/BF02940290. Cancer Chemother Pharmacol. 1990. PMID: 2322988
-
Vincristine- and bortezomib-induced neuropathies - from bedside to bench and back.Exp Neurol. 2021 Feb;336:113519. doi: 10.1016/j.expneurol.2020.113519. Epub 2020 Oct 29. Exp Neurol. 2021. PMID: 33129841 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous